Medicines Evaluation Unit Limited
Registered name: MEDICINES EVALUATION UNIT LIMITED
Part of Iqvia Holdings Inc. groupMedicines Evaluation Unit Limited made £2.4m profit in the year to 31 Dec 2025 (revenue not disclosed).
Medicines Evaluation Unit Limited reported £2.4m profit in the year to 31 Dec 2025; its revenue was not disclosed. It had 160 employees. The company is classified under “other research and experimental development on natural sciences and engineering” and is based in Reading; we hold 5 years of its filed accounts.
- Status
- Active
- Location
- Reading, South East
- Age
- 27 yrs · since 1999
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “IQVIA Limited acquired 100% of the share capital of the company on 13 June 2025, becoming the immediate parent company. IQVIA Limited is a company incorporated in the United Kingdom.”
Key figures
This company published its profit but not its turnover, so revenue and margins are not disclosed. We never estimate them.
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Mar 2022 | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | 31 Dec 2025 |
|---|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&L | Profit only |
| Profit & loss | |||||
| Revenue (turnover) | £17.1m | £17.6m | £18.2m | £18.2m | — |
| Cost of sales | £8m | £8.1m | £7.5m | £8m | £6.4m |
| Gross profit | £9.1m | £9.5m | £10.7m | £10.2m | — |
| Operating profit | £5.2m | £5.1m | £6.2m | £5.6m | — |
| Profit before tax | £5.5m | £5m | £7.1m | £6m | £2.6m |
| Profit after tax | £5.7m | £5.1m | £7.4m | £5.3m | £2.4m |
| Profit (best available) | £5.7m | £5.1m | £7.4m | £5.3m | £2.4m |
| Staff costs | £6m | £6.7m | £7.1m | £7.9m | £6.2m |
| Employees (average) | 140 | 162 | 149 | 160 | 160 |
| Ratios | |||||
| Profit margin | 33.1% | 29.3% | 40.5% | 29.4% | — |
| Gross margin | 53.3% | 54% | 58.7% | 56.1% | — |
| Revenue per employee | £122k | £108k | £122k | £114k | — |
| Profit per employee | £40.5k | £31.8k | £49.4k | £33.4k | £14.7k |
| Cash conversion | −79.9% | −112.6% | −80.8% | −118.8% | — |
| Growth (year on year) | |||||
| Revenue growth | — | ▲2.5% | ▲3.4% | ▲0.1% | — |
| Profit growth | — | ▼9.3% | ▲43% | ▼27.5% | — |
| Headcount growth | — | ▲15.7% | ▼8% | ▲7.4% | — |
| Balance sheet — indirect signals, not revenue | |||||
| Cash at bank | £12.6m | £16.6m | £19.5m | £33.2m | £8.1m |
| Net assets | £26.3m | £30.2m | £34.6m | £38.3m | £12.7m |
| Fixed assets | £10.5m | £10.2m | £10.8m | £3.1m | £3m |
| Current assets | £18.9m | £23.8m | £26.2m | £37.8m | £12.7m |
| Debtors | £1.7m | £2.3m | £3.5m | £850k | £2.7m |
| Deferred income | £2.6m | £3.6m | £2m | £1.4m | £1m |
| Cash from operations | −£4.1m | −£5.8m | −£5m | −£6.7m | −£2.1m |
| Source | Accounts · bulk data Dec 2023 | Accounts · bulk data Dec 2023 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Mar 2026 | FullAccounts · bulk data Sep 2026 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- £14.7k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now £12.7m
- Cash at bank
- —
- Now £8.1m
- Headcount
- —
- Now 160
- Deferred income
- —
- Now £1m
- Fixed assets
- —
- Now £3m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Iqvia Holdings Inc. (registered outside the UK register)ultimate parent75–100%
- Iqvia RDS UK Holdings Ltd.75–100%
- Iqvia RDS Holdings75–100%
- Iqvia Ltd.75–100%
- Medicines Evaluation Unit Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (28)
- Interface Clinical Services LtdRev. £26.3m · Profit £5.9m
- Oxford Conversis LimitedRev. £7.7m · Profit −£90.5k
- Pharmareview LimitedRev. £6m · Profit £47.8m
- Epg Communication Holdings LimitedRev. £2.5m · Profit −£4.3m
- Apira LimitedFigures not disclosed
- Arc Bio Communications LimitedRev. — · Profit £1.8m
- Clintec International Ltd.Figures not disclosed
- Cro Solutions LimitedRev. — · Profit £1.1m
- Drugdev LimitedFigures not disclosed
- Gce Clin Solutions LimitedFigures not disclosed
- Healthcare Business Information LimitedFigures not disclosed
- Ims (UK) Pension Plan Trustee Company LimitedFigures not disclosed
- Iqvia Biotech Ltd.Figures not disclosed
- Iqvia Investment Holdings LimitedFigures not disclosed
- Iqvia Solutions Finance UK V Ltd.Figures not disclosed
- Iqvia Solutions UK LimitedFigures not disclosed
- Iqvia Technology Services Ltd.Figures not disclosed
- LH Perspectives LimitedFigures not disclosed
- Linguamatics LimitedFigures not disclosed
- Linguamatics Solutions LimitedFigures not disclosed
- Optimum Contact LimitedFigures not disclosed
- Pharmadeals LimitedFigures not disclosed
- Pharmaspectra Group LtdRev. — · Profit £1.6m
- Pharmaspectra Topco LtdLiquidationFigures not disclosed
- PHR Topco LimitedLiquidationRev. — · Profit −£1.8m
- Prioritis LimitedFigures not disclosed
- Q Squared Solutions Holdings LimitedFigures not disclosed
- QH Research LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Charles River Laboratories Edinburgh LimitedOther research and experimental development on natural sciences and engineering
- Revenue
- £128m
- Profit
- £16.6m
- Staff
- 1,236
- Innovative Technology LimitedOldham · Other research and experimental development on natural sciences and engineering
- Revenue
- £63.6m
- Profit
- £9.9m
- Staff
- 207
- York Bioanalytical Solutions LimitedUpper Poppleton York · Other research and experimental development on natural sciences and engineering
- Revenue
- £11.1m
- Profit
- £3.6m
- Staff
- 82
- Drumgrange LimitedChertsey · Other research and experimental development on natural sciences and engineering
- Revenue
- £29.1m
- Profit
- £2.6m
- Staff
- 172
- Psi Cro UK LimitedKidlington · Other research and experimental development on natural sciences and engineering
- Revenue
- £17.9m
- Profit
- £1m
- Staff
- 145
- 42 Technology LimitedCambridge · Other research and experimental development on natural sciences and engineering
- Revenue
- £10.9m
- Profit
- £948k
- Staff
- 76
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit £2.4m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.